Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial

A new quinolone, zabofloxacin, has now been developed; hence, a non-inferiority trial is needed to compare this new compound with another widely used quinolone to examine its efficacy and safety for the treatment of chronic obstructive pulmonary disease (COPD) exacerbations. This was a prospective,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Int J Chron Obstruct Pulmon Dis
Autores principales: Rhee, Chin Kook, Chang, Jung Hyun, Choi, Eu gene, Kim, Hyun kuk, Kwon, Yong-Soo, Kyung, Sun Young, Lee, Ji-Hyun, Park, Myung Jae, Yoo, Kwang Ha, Oh, Yeon Mok
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622522/
https://ncbi.nlm.nih.gov/pubmed/26543359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/COPD.S90948
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares